Cardiff Oncology Inc expected to post a loss of 24 cents a share - Earnings Preview

Cardiff Oncology

25/02/2025 22:02

Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to show a fall in quarterly revenue when it reports  results on February 27 for the period ending December 31 2024

The San Diego California-based  company is expected to report a 39.6% decrease in revenue to $94.17 thousand from $156 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cardiff Oncology Inc is $11.50​, above​ its last closing price of $4.56. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.27
-0.27
-0.25
Beat
7.4
Jun. 30 2024
-0.25
-0.26
Missed
-5.1
Mar. 31 2024
-0.25
-0.25
-0.22
Beat
11.1​
Dec. 31 2023
-0.27
-0.28
-0.21
Beat
24.3
​​Sep. 30 2023
-0.28
-0.28
-0.22
Beat
22.8
Jun. 30 2023
-0.28
-0.26
-0.25
Beat
3.5​
Mar. 31 2023
-0.22
-0.23
-0.25
Missed
-10.6
Dec. 31 2022
-0.22
-0.23
-0.20
Beat
14.9

This summary was machine generated February 25 at 22:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)